Phospho-JAK2 (Tyr1007) Antibody [G9F22]

Application: Reactivity: Human, Mouse

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human, Mouse

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
130 kDa 125 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
Phospho-JAK2 (Tyr1007) Antibody [G9F22] detects endogenous levels of total JAK2 protein only when it is phosphorylated at Tyr1007.

Clone
G9F22

Synonym(s)
JAK-2, JAK2, Janus kinase 2, Janus kinase 2 (a protein tyrosine kinase), JTK10, Tyrosine-protein kinase JAK2

Background
Phospho-JAK2 (Tyr1007) represents the activated form of the non‑receptor tyrosine kinase JAK2, a member of the Janus kinase family that functions as the principal catalytic signaling module for many class I and class II cytokine receptors, including receptors for erythropoietin, thrombopoietin, growth hormone, interleukins, and interferons. The protein contains an N‑terminal FERM domain that mediates constitutive association with the proximal cytoplasmic regions of cytokine receptors, followed by an SH2‑like domain, an autoregulatory pseudokinase domain (JH2), and a C‑terminal tyrosine kinase domain (JH1) that harbors the activation loop containing Tyr1007 and the adjacent Tyr1008. Cytokine binding to the extracellular domains of pre‑associated receptor dimers induces conformational rearrangements that juxtapose two receptor‑bound JAK2 molecules, allowing trans‑autophosphorylation of Tyr1007 within the activation loop; phosphorylation at this position is required for full catalytic activity and stabilizes an active conformation of the kinase domain that efficiently phosphorylates receptor cytoplasmic tails and downstream substrates. The phosphorylated activation loop promotes substrate access and increases catalytic turnover, and the same conformational change relieves inhibitory constraints imposed by the pseudokinase domain, which normally restrains JAK2 activity, such that Tyr1007 phosphorylation serves as a central switch for transitioning from a latent receptor‑bound state to an active signaling kinase. Activated phospho‑JAK2 (Tyr1007) phosphorylates tyrosine residues on associated cytokine receptors, creating docking sites for SH2‑domain‑containing signaling proteins, most prominently STAT transcription factors, which recognize specific receptor phosphotyrosines, become phosphorylated by JAK2 on their own critical tyrosine, dimerize, and translocate to the nucleus to drive transcriptional programs that control proliferation, differentiation, survival, and immune effector functions. Additional substrates that bind phosphorylated receptor–JAK2 complexes include adaptor proteins such as Shc, insulin receptor substrates, and focal adhesion kinase, which couple phospho‑JAK2 output into Ras–MAPK, PI3K–Akt, and adhesion‑related pathways, extending the influence of Tyr1007‑dependent activation beyond the canonical JAK–STAT axis to broader mitogenic and migratory signaling networks. The phosphorylation state of Tyr1007 is tightly regulated by the balance between upstream cytokine inputs, kinase autophosphorylation, and protein tyrosine phosphatases, and the homologous activation‑loop tyrosines in related JAK family members and Tyk2 share analogous roles, underscoring the conserved requirement for activation‑loop phosphorylation in controlling Janus kinase output. Dysregulation of JAK2 activation at or upstream of Tyr1007, including mutations in the pseudokinase domain that weaken its inhibitory effect and permit constitutive activation loop phosphorylation, associates with myeloproliferative neoplasms and inflammatory pathologies characterized by excessive JAK–STAT signaling.

Background

Phospho-JAK2 (Tyr1007) represents the activated form of the non‑receptor tyrosine kinase JAK2, a member of the Janus kinase family that functions as the principal catalytic signaling module for many class I and class II cytokine receptors, including receptors for erythropoietin, thrombopoietin, growth hormone, interleukins, and interferons. The protein contains an N‑terminal FERM domain that mediates constitutive association with the proximal cytoplasmic regions of cytokine receptors, followed by an SH2‑like domain, an autoregulatory pseudokinase domain (JH2), and a C‑terminal tyrosine kinase domain (JH1) that harbors the activation loop containing Tyr1007 and the adjacent Tyr1008. Cytokine binding to the extracellular domains of pre‑associated receptor dimers induces conformational rearrangements that juxtapose two receptor‑bound JAK2 molecules, allowing trans‑autophosphorylation of Tyr1007 within the activation loop; phosphorylation at this position is required for full catalytic activity and stabilizes an active conformation of the kinase domain that efficiently phosphorylates receptor cytoplasmic tails and downstream substrates. The phosphorylated activation loop promotes substrate access and increases catalytic turnover, and the same conformational change relieves inhibitory constraints imposed by the pseudokinase domain, which normally restrains JAK2 activity, such that Tyr1007 phosphorylation serves as a central switch for transitioning from a latent receptor‑bound state to an active signaling kinase. Activated phospho‑JAK2 (Tyr1007) phosphorylates tyrosine residues on associated cytokine receptors, creating docking sites for SH2‑domain‑containing signaling proteins, most prominently STAT transcription factors, which recognize specific receptor phosphotyrosines, become phosphorylated by JAK2 on their own critical tyrosine, dimerize, and translocate to the nucleus to drive transcriptional programs that control proliferation, differentiation, survival, and immune effector functions. Additional substrates that bind phosphorylated receptor–JAK2 complexes include adaptor proteins such as Shc, insulin receptor substrates, and focal adhesion kinase, which couple phospho‑JAK2 output into Ras–MAPK, PI3K–Akt, and adhesion‑related pathways, extending the influence of Tyr1007‑dependent activation beyond the canonical JAK–STAT axis to broader mitogenic and migratory signaling networks. The phosphorylation state of Tyr1007 is tightly regulated by the balance between upstream cytokine inputs, kinase autophosphorylation, and protein tyrosine phosphatases, and the homologous activation‑loop tyrosines in related JAK family members and Tyk2 share analogous roles, underscoring the conserved requirement for activation‑loop phosphorylation in controlling Janus kinase output. Dysregulation of JAK2 activation at or upstream of Tyr1007, including mutations in the pseudokinase domain that weaken its inhibitory effect and permit constitutive activation loop phosphorylation, associates with myeloproliferative neoplasms and inflammatory pathologies characterized by excessive JAK–STAT signaling.

References
https://pubmed.ncbi.nlm.nih.gov/9111318/ https://pubmed.ncbi.nlm.nih.gov/29379470/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%